Three Sinovac doses fail to protect against Omicron in study


BEIJING (Bloomberg): Two doses and a booster of the Covid-19 vaccine made by China’s Sinovac Biotech Ltd, one of the most widely used in the world, didn’t produce sufficient levels of neutraliSing antibodies to protect against the Omicron variant, a laboratory study found.

For those who are fully immunised with the vaccine known as CoronaVac, getting a booster shot from Germany’s BioNTech SE significantly improved protective levels of antibodies against omicron, according to the study from the University of Hong Kong and The Chinese University of Hong Kong.

The Star Christmas Special Promo: Save 35% OFF Yearly. T&C applies.

Monthly Plan

RM 13.90/month

Best Value

Annual Plan

RM 12.33/month

RM 8.02/month

Billed as RM 96.20 for the 1st year, RM 148 thereafter.

Follow us on our official WhatsApp channel for breaking news alerts and key updates!
China , Sinovac , booster , vaccine

Next In Aseanplus News

China food delivery platform names Jay Chou as brand ambassador, supported by lookalikes
Oman says foreign minister met Saudi counterpart to discuss Yemen
Asean Cup - Looking back: Singapore's Asean football success on the shoulder of Sasikumar
Asean news headlines as at 10pm on Wednesday (Dec 31)
World begins to welcome 2026 after a year of Trump, truces and turmoil
Xi says China to hit 2025 growth target of 'around 5 per cent'
Community service orders to take effect tomorrow to curb minor littering
Sydney brings in New Year with nod to victims of Bondi attack
Singapore economy grew 4.8% in 2025, strategy must be refreshed to stay competitive: PM Wong
GOF says it has nabbed over 1,600 people, seized goods worth RM1.1bil in 2025

Others Also Read